Efficacy and safety of bilastine 20mg compared with cetirizine 10mg and placebo in the treatment of perennial allergic rhinitis

Current Medical Research and Opinion

Volumn 28, Issue 1, 2012, Pages 121-130

  Sastre, Joaquín ^a   Mullol, Joaquim ^b   Valero, Antonio ^b   Valiente, Román ^c  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c FAES FARMA SA   (Spain)

Author keywords

Bilastine; Cetirizine; H1 antihistamine; PAR; Perennial allergic rhinitis

Indexed keywords

BILASTINE; CETIRIZINE; PLACEBO;

ABDOMINAL PAIN; ADULT; APPETITE; AREA UNDER THE CURVE; ARTICLE; BLOOD CHEMISTRY; BLOOD EXAMINATION; CONTROLLED STUDY; DIET RESTRICTION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELECTROCARDIOGRAM; EYE DISEASE; FATIGUE; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORNING DOSAGE; MULTICENTER STUDY; NASAL PRURITUS; NAUSEA; NOSE CONGESTION; OUTCOME ASSESSMENT; PERENNIAL RHINITIS; PHYSICAL EXAMINATION; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RHINORRHEA; RISK ASSESSMENT; SCREENING; SIDE EFFECT; SNEEZING; SOMNOLENCE; SORE THROAT; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS; VISUAL ANALOG SCALE; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; ARGENTINA; BENZIMIDAZOLES; CETIRIZINE; CHILD; DOSAGE FORMS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERIDINES; PLACEBOS; RHINITIS, ALLERGIC, PERENNIAL; SOUTH AFRICA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855933735     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.640667     Document Type: Article

References (17)

1. Bauchau V, Durham SR. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 2005;60:350-3 (Pubitemid 40293352)
2. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160 (Pubitemid 351357811)
3. Howarth PH. Antihistamines in rhinoconjunctivitis. In: Simons FER (ed.) Histamine and H1-Antihistamines in Allergic Disease, 2nd edn. New York: Marcel Dekker Inc., 2002:179-200
4. Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5mg in seasonal allergic rhinitis patients. Allergy 2009;64:158-65
5. Kuna P, Bachert C, Nowacki Z, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009;39:1338-47
6. Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010;65:516-28
7. Bachert C, Kuna P, Zuberbier T. Bilastine in allergic rhinitis and urticaria. Allergy 2010;65(Suppl 93):1-13
8. Jauregizar N, de la Fuente L, Lucero ML, et al. Pharmacokinetic- pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet 2009;48:543-54
9. Corcó stegui R, Labeaga L, Innerá rity A, et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D 2006;7:219-31 (Pubitemid 43927202)
10. Corcó stegui R, Labeaga L, Innerá rity A, et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005;6:371-84 (Pubitemid 41633390)
11. Mansmann Jr H, Altman RA, Berman BA, et al. Efficacy and safety of cetirizine therapy in perennial allergic rhinitis. Ann Allergy 1992; 68:348-53
12. Murris-Espin M, Melac M, Charpentier JC, et al. Comparison of efficacy and safety of cetirizine and ebastine in patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 1998;80:399-403 (Pubitemid 28246771)
13. Bousquet J, Duchateau J, Pignat JC, et al. Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996;98:309-16
14. Benninger M, Farrar JR, Blaiss M, et al. Evaluating approved medications to treat allergic rhinitis in the United States: an evidence-based review of efficacy for nasal symptoms by class. Ann Allergy Asthma Immunol 2010;104:13-29
15. Lu S, Malice MP, Dass SB, et al. Clinical studies of combination montelukast and loratadine in patients with seasonal allergic rhinitis. J Asthma 2009;46:878-83
16. Mansfield LE, Hampel F, Haeusler JM, et al. Study of levocetirizine in seasonal allergic rhinitis. Curr Med Res Opin 2010;26:1269-75
17. Baraniuk JN. The placebo effect: plugging the nostrils of unmet needs. Curr Allergy Asthma Rep 2009;9:149-52